Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Schizophrenia: full-pipeline trial registry
76 of 318 indexed Schizophrenia trials are currently recruiting.
Corpus placement: #23 of 28,707 conditions by registered trial count.
318 US clinical trials · 76 currently recruiting · #23 of 28,707 conditions by registered trial count
Schizophrenia: 318 US clinical trials tracked, 76 recruiting.
Schizophrenia is the subject of 318 registered US clinical trials on ClinicalTrials.gov, 76 of them currently open to new participants. 90 are in Phase 3-4 (later-stage) and 87 in Phase 1-2 (earlier-stage). The most active sponsor is University of Maryland, Baltimore, running 14 of these trials.
Enrollment posture brief
Registry condition schizophrenia
OPEN 76 | RECR 24% | LATE 90 | EARLY 87 | RANK #23 | SPON 14
Volume-matched condition peers
Nearest open-share peer: Dehydration (24% recruiting · 21 trials)
Schizophrenia lists 76 open slots (24% of 318 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Schizophrenia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Schizophrenia is recruiting below its size-band peers.
76 of 318 indexed trials (23.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Schizophrenia trials is spread across many organizations.
University of Maryland, Baltimore accounts for 14 of 318 trials (4.4%). 129 distinct sponsors appear on at least one study for this condition label.
-
Typical Schizophrenia enrolment sits around 83 participants.
Median target enrolment is 83 among the 316 trials that report a genuine target (sentinel values excluded). 169 of those (53.5%) plan for fewer than 100 participants.
-
Schizophrenia research is mostly interventional.
290 interventional and 28 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
318 total, page 7 of 7
Add On Treatment for Cognitive Deficits in Schizophrenia
University of Pennsylvania
NCT01346163
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
Luye Pharma Group
NCT02186769
Effects of Antipsychotic Medications on Energy Intake and Expenditure
Washington University School of Medicine
NCT00836251
Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia
NYU Langone Health
NCT05643196
Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate Cortex Activation in Schizophrenia
Indiana University
NCT04309370
Varenicline Effects In Schizophrenic Smokers
Nathan Kline Institute for Psychiatric Research
NCT00548470
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
Vanda Pharmaceuticals
NCT04127058
A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women
Otsuka Pharmaceutical Development & Commercialization
NCT07305779
Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia
Beth Israel Deaconess Medical Center
NCT00434980
Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)
National Institute of Mental Health (NIMH)
NCT00001768
Nicotinic Receptors and Schizophrenia
VA Office of Research and Development
NCT00952393
eMove - Dance/Movement Therapy Study
Drexel University
NCT05712928
Improving Neurocognitive Deficits and Function in Schizophrenia With Transcranial Magnetic Stimulation
VA Office of Research and Development
NCT03037983
An Open-Label Trial of Tocilizumab in Schizophrenia
Brian Miller
NCT01696929
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
University of Colorado, Denver
NCT00149734
Integrated Coping and Awareness Training
University of North Carolina, Chapel Hill
NCT02400502
A Comparison of Seroquel vs. Risperidone in Schizophrenia
AstraZeneca
NCT00034905
Generalization of Training in Schizophrenia
US Department of Veterans Affairs
NCT00108199
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 40 |
| Phase 3 | 50 |
| Phase 4 | 40 |
Top Sponsors
Named interventions
Most-linked intervention names on Schizophrenia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Schizophrenia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Schizophrenia page
318 registered trials, 76 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 76 Schizophrenia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Maryland, Baltimore sponsors the most Schizophrenia trials on record, review their full trial history before evaluating a specific study. See University of Maryland, Baltimore's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Schizophrenia condition card totals 318 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.